Editor's Note: An earlier version of this story said David Whitrap called many patient advocates "pharma front groups." He did not mention patient advocates in his statement. The headline and first paragraph also have been changed to clarify that ICER has always allowed policymakers the option of not using QALYs. The drug-appraisal nonprofit ICER is willing to exclude quality-adjusted life years ​from value assessments and rely on the other metrics it already uses to determine fair drug...